Digital-Pathology-Today Por arte de portada

Digital-Pathology-Today

De: Magpie Communications
Escúchala gratis

  • Resumen

  • Digital Pathology Today, the only podcast for professionals interested in the field of digital pathology and artificial intelligence in a clinical setting. This interview-style podcast features industry leaders, key academics, and top pathologists discussing the past, present and future of digital pathology. Hosted by pathologist, Dr. Joseph Anderson, each weekly episode discusses topics from artificial intelligence to regulation and much more. “We hope to bring news and information to anyone interested in the field of digital pathology,” said Digital Pathology Today host, Dr. Joseph Anderson. “With so many advances and innovations taking place, we know that Digital Pathology Today will be a valuable source of information for our listeners.”
    Copyright Magpie Communications
    Más Menos
activate_primeday_promo_in_buybox_DT
Episodios
  • June 2024 Digital Pathology Roundup

    June 2024 Digital Pathology Roundup
    Jul 11 2024
    A lot to talk about in June… ZayaAI introduced a Pathology Laboratory Information System (LIS), addressing integration issues between digital pathology IMS and outdated lab software. The acquisition of Visonex by PreciPoint further indicates market convergence. PathAI launched two AI products: PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™, aimed at single-cell image analysis for biomarker discovery and companion diagnostics. Roche gained FDA 510(k) clearance for its VENTANA DP 200 scanner, marking rapid growth in the US market amidst increased regulation. Tempus AI went public, providing digital pathology services and patient data access, competing with vendors like Paige and PathAI through advanced algorithms for IHC and H&E staining. Imogen Fitt is Senior Market Analyst at Signify Research. During her tenure Imogen has completed studies on digital pathology, LabIT and the use of AI in drug development, expanding Signify Research’s diagnostics and life sciences business coverage.
    Más Menos
    13 m
  • SEASON 3, EPISODE 14 - Alan Lorimer - Digital Pathology in the Cloud

    SEASON 3, EPISODE 14 - Alan Lorimer - Digital Pathology in the Cloud
    Jun 28 2024
    Moving digital pathology to the cloud. We're talking about cloud computing the features and components of the cloud and how it differs from on premise computing. What are the barriers and overlooked considerations in moving your operations to the cloud? What is the truth about storage costs in 2024? Is it still a concern or have the gains been eaten away by the increasingly large amounts of data we continue to generate? How can cloud computing unlock exciting new applications at a lower cost for organizations? And finally we discuss regulatory considerations for the cloud from the perspective of the FDA EU, GD CP and GCP in developing new drugs and diagnostics. Alan Lorimer, started his professional journey as an electronics engineer at the BBC. Over his 40-year career, he's founded or led four successful businesses. Notably, he drove an IT hosting company to a successful exit in 2011. He then specialized in IT due diligence for around 60 European companies going through some kind of transaction, sharpening his analytical prowess. In 2016, Alan pivoted to digital pathology, creating the innovative QDPconnect with OracleBio, leading to the launch of Sciento Technology. Alan's journey from the BBC to cloud computing exemplifies his relentless drive for tech innovation and industry impact.
    Más Menos
    31 m
  • SEASON 3, EPISODE 13 - Andre Esteva, PhD - Personalizing Treatment Decisions through Artificial Intelligence

    SEASON 3, EPISODE 13 - Andre Esteva, PhD - Personalizing Treatment Decisions through Artificial Intelligence
    Jun 20 2024
    Today we are discussing how treatment decisions can be personalized through artificial intelligence and digital pathology. Our guest is Andre Esteva of Artera. Atera’s first product is in prostate cancer. We discuss how AI can improve upon the current state of the practice which largely relies on making decisions based on clinical nomograms. We discuss the concepts prediction and prognosis and how both are incorporated into treatment decisions; what goes into developing and validating AI based algorithms in digital pathology and the importance of validating these algorithms in the appropriate studies specifically randomized clinical trials. There is one huge advantage of AI based digital pathology tools over genomics and molecular tools. Image based tools can be performed instantaneously rather than waiting days to weeks. Andre Esteva is a researcher and entrepreneur in medical artificial intelligence. He currently serves as CEO of Artera and was previously Head of Medical AI at Salesforce Research. He has worked at Google Research, Sandia National Labs, GE Healthcare, and has founded four companies. His research efforts have largely focused on medical AI diagnostics and precision medicine. His publications have made the covers of Nature and Nature Medicine, and have been featured in Cell, The Lancet, NeurIPS, and similar venues. These works have been widely covered by the WSJ, Fortune, BBC, The Economist, and hundreds of other news outlets.
    Más Menos
    27 m
Enfermedades Físicas Hygiene & Healthy Living Política y Gobierno Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre Digital-Pathology-Today

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles